AI Article Synopsis
- The study assessed the long-term effectiveness of intratympanic methylprednisolone treatment for patients with intractable Ménière's disease.
- Sixteen patients were followed for over two years, showing a 94% short-term and 81% long-term control rate for vertigo, along with similar improvements in functional activity.
- The findings suggest that this treatment can effectively manage symptoms while preserving hearing, making it a possible alternative for managing this challenging condition.
Article Abstract
Objective: This study aimed to investigate the long-term efficacy of intratympanic methylprednisolone perfusion treatment for intractable Ménière's disease.
Methods: A retrospective analysis of 17 intractable Ménière's disease patients treated with intratympanic methylprednisolone perfusion was performed. Treatment efficacy was evaluated according to the American Academy of Otolaryngology-Head and Neck Surgery criteria. Short and long-term control or improvement rates were calculated after 6 and 24 months, respectively.
Results: Sixteen patients were followed for more than two years. Short- and long-term vertigo control rates were 94 per cent and 81 per cent, respectively; short- and long-term functional activity improvements were 94 per cent and 88 per cent, respectively. The pure tone average was 53 ± 14 dB before treatment, and 50 ± 16 dB at 6 months and 52 ± 20 dB at 24 months after intratympanic methylprednisolone perfusion. Tinnitus was controlled or improved in five patients over the two-year follow-up period.
Conclusion: Intratympanic methylprednisolone perfusion can effectively control vertigo and improve functional activity in intractable Ménière's disease patients with good hearing preservation. It may therefore be a viable alternative treatment for intractable Ménière's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S0022215115000171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison between intratympanic injection of dexamethasone and methylprednisolone in idiopathic sudden sensorineural hearing loss: A randomized clinical trial.
Laryngoscope Investig Otolaryngol
December 2024
Hearing Disorders Research Center, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences Tehran Iran.
Objective: To compare the hearing outcomes of patients with idiopathic sudden sensorineural hearing loss after intratympanic (IT) injection of methylprednisolone and dexamethasone.
Study Design: Randomized case-controlled clinical trial.
Methods: Seventy-five patients diagnosed with idiopathic sensorineural hearing loss were randomly divided into two groups based on therapy.
Up-regulation of HIF-1α in refractory sudden sensorineural hearing loss.
Acta Otorhinolaryngol Ital
October 2024
Department of Otolaryngology-Head and Neck Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
Objectives: To investigate the expression of hypoxia-inducible factor-1α (HIF-1α) in patients with refractory sudden sensorineural hearing loss (SSNHL).
Material And Methods: Thirty patients with refractory SSNHL were treated with intratympanic methylprednisolone perfusion (IMP) for 10 days. Expression of HIF-1α and histone deacetylase 2 (HDAC2) was evaluated in peripheral blood mononuclear cells (PBMCs) and .
A Randomised Controlled Trial Comparing Intratympanic Gentamicin with Methylprednisolone in Meniere's Disease with Good Hearing.
Indian J Otolaryngol Head Neck Surg
October 2024
Department of ENT, Christian Medical College, Vellore, Tamil Nadu India.
Unlabelled: A randomized prospective parallel group trial was done to compare the efficacy of intratympanic low dose gentamicin with methylprednisolone in treating intractable unilateral Meniere's disease with serviceable hearing.
Study Design: Randomised prospective parallel group trial.
Setting: Tertiary care centre in South India.
The effectiveness of intratympanic injections with methylPREDnisolon versus placebo in the treatment of vertigo attacks in MENière's disease (PREDMEN trial): a study protocol for a phase-3 multicentre, double-blinded, randomised, placebo-controlled trial.
BMJ Open
August 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands.
Introduction: Intratympanic corticosteroids are commonly used in the treatment of Menière's disease (MD). However, few and small randomised controlled trials (RCT) on the effectiveness of intratympanic corticosteroids have been performed. A recent Cochrane review suggested that a well-conducted placebo-controlled RCT with a large study population is required to evaluate the effectiveness of the use of intratympanic corticosteroids in MD.
View Article and Find Full Text PDFPrognostic Factors in Idiopathic Sudden Sensorineural Hearing Loss: The Experience of Two Audiology Tertiary Referral Centres.
Medicina (Kaunas)
July 2024
Phoniatrics and Audiology Unit, Department of Neuroscience DNS, University of Padova, 31100 Treviso, Italy.
: Although different hypotheses have been proposed over time, there is a dearth of information on factors able to predict the response to treatment for idiopathic sudden sensorineural hearing loss (ISSNHL) and hearing recovery. The aim of this study was to apply univariate and multivariate statistical models in a retrospective clinical setting of patients given therapy for ISSNHL at our tertiary academic audiological centers to investigate the prognostic value of clinical signs, symptoms, and comorbidities in relation to hearing recovery. : The inclusion criteria were: history of ISSNHL diagnosed and treated at the Padova or Modena tertiary academic audiological centers; age ≥ 18 years; availability of clinical and audiological outcome data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!